SR-B1-targeted nanodelivery of anti-cancer agents: a promising new approach to treat triple-negative breast cancer

Rebecca Johnson,1 Nirupama Sabnis,2 Xiangle Sun,1 Ruhani Ahluwalia,3 Andras G Lacko2,4 1Institute of Molecular Medicine, 2Institute for Cardiovascular and Metabolic Diseases, University of North Texas Health Science Center, 3Harmony School of Innovation, 4Department of Pediatrics, University of Nort...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Johnson R, Sabnis N, Sun X, Ahluwalia R, Lacko AG
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	breast cancer TNBC rHDL nanoparticles SR-B1 receptors targeted drug delivery lapatinib valrubicin Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/f7262946c78546ec9f27e10edded8f4c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f7262946c78546ec9f27e10edded8f4c
record_format	dspace
spelling	oai:doaj.org-article:f7262946c78546ec9f27e10edded8f4c2021-12-02T02:28:00ZSR-B1-targeted nanodelivery of anti-cancer agents: a promising new approach to treat triple-negative breast cancer1179-1314https://doaj.org/article/f7262946c78546ec9f27e10edded8f4c2017-06-01T00:00:00Zhttps://www.dovepress.com/sr-b1-targeted-nanodelivery-of-anti-cancer-agents-a-promising-new-appr-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314Rebecca Johnson,1 Nirupama Sabnis,2 Xiangle Sun,1 Ruhani Ahluwalia,3 Andras G Lacko2,4 1Institute of Molecular Medicine, 2Institute for Cardiovascular and Metabolic Diseases, University of North Texas Health Science Center, 3Harmony School of Innovation, 4Department of Pediatrics, University of North Texas Health Science Center, Fort Worth, TX, USA Abstract: Patients with triple-negative breast cancer (TNBC) have a considerably less favorable prognosis than those with hormone-positive breast cancers. TNBC patients do not respond to current endocrine treatment and have a 5-year survival prognosis of <30%. The research presented here is intended to fill a void toward the much needed development of improved treatment strategies for metastatic TNBC. The overall goal of this research was to evaluate the effectiveness of reconstituted high-density lipoprotein (rHDL) nanoparticles (NPs) as delivery agents for anti-TNBC drugs. Using lapatinib and valrubicin as components of the rHDL/drug complexes resulted in a significantly better performance of the NP-transported drugs compared with their free (unencapsulated) counterparts. The enhancement of the therapeutic effect and the protection of normal cells (cardiomyocytes) achieved via the rHDL NPs were likely due to the overexpression of the high-density lipoprotein (HDL) (scavenger receptor class B type 1 [SR-B1]) receptor by the TNBC cells. Keywords: breast cancer, TNBC, rHDL nanoparticles, SR-B1 receptors, targeted drug delivery, lapatinib, valrubicinJohnson RSabnis NSun XAhluwalia RLacko AGDove Medical Pressarticlebreast cancerTNBCrHDL nanoparticlesSR-B1 receptorstargeted drug deliverylapatinibvalrubicinNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol Volume 9, Pp 383-392 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	breast cancer TNBC rHDL nanoparticles SR-B1 receptors targeted drug delivery lapatinib valrubicin Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	breast cancer TNBC rHDL nanoparticles SR-B1 receptors targeted drug delivery lapatinib valrubicin Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Johnson R Sabnis N Sun X Ahluwalia R Lacko AG SR-B1-targeted nanodelivery of anti-cancer agents: a promising new approach to treat triple-negative breast cancer
description	Rebecca Johnson,1 Nirupama Sabnis,2 Xiangle Sun,1 Ruhani Ahluwalia,3 Andras G Lacko2,4 1Institute of Molecular Medicine, 2Institute for Cardiovascular and Metabolic Diseases, University of North Texas Health Science Center, 3Harmony School of Innovation, 4Department of Pediatrics, University of North Texas Health Science Center, Fort Worth, TX, USA Abstract: Patients with triple-negative breast cancer (TNBC) have a considerably less favorable prognosis than those with hormone-positive breast cancers. TNBC patients do not respond to current endocrine treatment and have a 5-year survival prognosis of <30%. The research presented here is intended to fill a void toward the much needed development of improved treatment strategies for metastatic TNBC. The overall goal of this research was to evaluate the effectiveness of reconstituted high-density lipoprotein (rHDL) nanoparticles (NPs) as delivery agents for anti-TNBC drugs. Using lapatinib and valrubicin as components of the rHDL/drug complexes resulted in a significantly better performance of the NP-transported drugs compared with their free (unencapsulated) counterparts. The enhancement of the therapeutic effect and the protection of normal cells (cardiomyocytes) achieved via the rHDL NPs were likely due to the overexpression of the high-density lipoprotein (HDL) (scavenger receptor class B type 1 [SR-B1]) receptor by the TNBC cells. Keywords: breast cancer, TNBC, rHDL nanoparticles, SR-B1 receptors, targeted drug delivery, lapatinib, valrubicin
format	article
author	Johnson R Sabnis N Sun X Ahluwalia R Lacko AG
author_facet	Johnson R Sabnis N Sun X Ahluwalia R Lacko AG
author_sort	Johnson R
title	SR-B1-targeted nanodelivery of anti-cancer agents: a promising new approach to treat triple-negative breast cancer
title_short	SR-B1-targeted nanodelivery of anti-cancer agents: a promising new approach to treat triple-negative breast cancer
title_full	SR-B1-targeted nanodelivery of anti-cancer agents: a promising new approach to treat triple-negative breast cancer
title_fullStr	SR-B1-targeted nanodelivery of anti-cancer agents: a promising new approach to treat triple-negative breast cancer
title_full_unstemmed	SR-B1-targeted nanodelivery of anti-cancer agents: a promising new approach to treat triple-negative breast cancer
title_sort	sr-b1-targeted nanodelivery of anti-cancer agents: a promising new approach to treat triple-negative breast cancer
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/f7262946c78546ec9f27e10edded8f4c
work_keys_str_mv	AT johnsonr srb1targetednanodeliveryofanticanceragentsapromisingnewapproachtotreattriplenegativebreastcancer AT sabnisn srb1targetednanodeliveryofanticanceragentsapromisingnewapproachtotreattriplenegativebreastcancer AT sunx srb1targetednanodeliveryofanticanceragentsapromisingnewapproachtotreattriplenegativebreastcancer AT ahluwaliar srb1targetednanodeliveryofanticanceragentsapromisingnewapproachtotreattriplenegativebreastcancer AT lackoag srb1targetednanodeliveryofanticanceragentsapromisingnewapproachtotreattriplenegativebreastcancer
_version_	1718402506064658432

SR-B1-targeted nanodelivery of anti-cancer agents: a promising new approach to treat triple-negative breast cancer

Ejemplares similares